HanAll Biopharma Invests in Interon to Seek Collaboration Op..
- Applications for Indonesian physicians are now open until April 9, 2024, at 23:59.
- Presents medical affairs as a new rotation in
collaboration with Daewoong Group.
- The Pharmaceutical Industry Fellowship Program
provides physicians with the opportunity to experience the various stages of
the drug development process.
HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company dedicated to advancing healthcare through innovation and excellence in drug development, opens applications for its prestigious Fellowship Program.
Tailored to offer extensive training across diverse aspects of the
pharmaceutical sector, this program presents a distinctive opportunity for
Indonesian physicians to immerse themselves in dynamic global environments. The
application period for the program will run from March 14 to April 9, 2024.
The
HanAll Pharmaceutical Industry Fellowship Program aims to cultivate
well-rounded physicians by offering rotations in four key areas of drug
development: Clinical and Pre-clinical, Operations and Regulatory Affairs,
Medical Affairs, and Business Development.
This
year, in collaboration with Daewoong Group, the program introduces medical
affairs as a new rotation. All participants in this program will operate under
a hybrid model, spending approximately six months at the Jakarta office and the
remainder working from home.
Selected
participants will play a crucial role in providing insights for pre-clinical
and translational work, contributing to clinical development plans, fostering
relationships with scientific experts including Key Opinion Leaders, and
tracking scientific developments in relevant therapeutic areas such as
neurology, oncology, immunology and ophthalmology.
Interested
candidates must hold an MD degree from Indonesia and demonstrate strong written
and oral English communication skills to apply to this program. A keen interest
in drug development, including preclinical and clinical phases, is essential,
along with a curiosity for learning from different cultures. While experience
in immunology, neurology, ophthalmology, or oncology is preferred, it is not
mandatory. Candidates must also commit to reside in Indonesia throughout the
two-year duration of the fellowship program.
Medical
doctors with various competencies, including executive communication,
problem-solving, and cross-cultural awareness, are encouraged to apply.
Prospective fellows should exhibit proactive, dynamic personalities while also
being team players, demonstrating agility and resilience in their approach.
“This
program provides an eye-opening experience, introducing me to innovative career
paths beyond traditional medical practice that I had never considered before.
As a medical doctor, this fellowship has not only provided me with invaluable
insights and knowledge not covered in medical school but also offered me
international exposure through mentorship, broadening my perspective on the
global healthcare landscape and the diverse opportunities within the sector,”
commented Dr. Soraya Arifa, a participant in the program in 2022.
To
apply, applicants are required to fill out the application form on the VIVIDAPP
website, which is accessible by clicking on the banner on HanAll’s official
website. The application form requires attaching a CV, an introduction video,
and transcripts. Successful applicants will benefit from a hybrid work
environment, annual paid leave, severance pay, experienced mentorship, and
comprehensive employee benefits, including insurance.
About HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a
global biopharmaceutical company with a presence in Korea, the USA, Japan, and
Indonesia with a mission of making meaningful contributions to patients' lives
by introducing innovative, impactful medicines to address severe unmet medical
needs. HanAll has been operating a portfolio of pharmaceutical products in the
areas of endocrine, circulatory, and urologic diseases for 51 years.
HanAll has also expanded its focus to
immunology, oncology, neurology, and ophthalmology to discover and develop
innovative medicines for patients with diseases for which there are no
effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an
anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the
world for the treatment of autoimmune diseases including myasthenia gravis
(MG), thyroid eye disease (TED), chronic inflammatory demyelinating
polyneuropathy (CIDP), and Graves’ disease (GD). Another main asset, HL036
(INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3
clinical studies in the US and China for the treatment of dry eye disease. For
further information, visit our website and
connect with us on LinkedIn. For
any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).
Disclaimer Statement
The contents of this
announcement include statements that are, or may be deemed to be,
"forward-looking statements." These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates,"
"expects," "intends," "may," "will," or
"should," and include statements HANALL (the company, we) makes
concerning its 2024 business and financial outlook and related plans; the
therapeutic potential of its product candidates; the intended results of its
strategy and the company, and its collaboration partners', advancement of, and
anticipated clinical development, data readouts and regulatory milestones and
plans, including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the timing and outcome of
regulatory filings and regulatory approvals. By their nature, forward-looking
statements involve risks and uncertainties, and readers are cautioned that any
such forward-looking statements are not guarantees of future performance. The
company's actual results may differ materially from those predicted by the
forward-looking statements. These may include various significant factors, such
as our expectations regarding the inherent uncertainties associated with
competitive developments, preclinical and clinical trial and product
development activities, and regulatory approval requirements. In addition,
performance may be affected by our reliance on collaborations with third
parties, estimating the commercial potential of our product candidates, our
ability to obtain and maintain protection of intellectual property of
technologies and drugs, our limited operating history, and our ability to
obtain additional funding for operations and to complete the development and
commercialization of product candidates. A further list and description of
these risks, uncertainties, and other risks can be found in Korea Stock
Exchange (KRX) filings and reports, including in our most recent annual report
as well as subsequent filings and reports filed by the company with the KRX.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document. We undertake no
obligation to publicly update or revise the information in this press release,
including any forward-looking statements, except as may be required by Korean
law and regulations.